

30 May 2021 |

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world's first positive Phase III data for a microbiome therapy; Adaptimmune's plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer's.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 May 2021, including: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world's first positive Phase III data for a microbiome therapy; Adaptimmune's plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer's.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Five Late-Breakers To Watch For At ASCO 2021](#)" - Scrip, 20 May, 2021.)

(Also see "[More Small Biotechs Are Launching Drugs On Their Own](#)" - Scrip, 20 May, 2021.)

(Also see "[Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line](#)" - Scrip, 24 May, 2021.)

(Also see "[Adaptimmune 'Neck And Neck' For First Solid Tumor T-Cell Therapy Nod For Afami-Cel](#)"

- Scrip, 21 May, 2021.)

(Also see "[\*Novo Nordisk's Keenly Awaited Semaglutide Trial To 'Redefine' Alzheimer's?\*](#)" - Scrip, 25 May, 2021.)

[Click here to explore this interactive content online](#) ✎